The companies agreed to share profits for the therapy equally in the U.S. and Europe, but Roche will have exclusive rights to commercialization in the rest of the world.

Roche has reported early clinical data with its candidate obesity therapy CT-388, bought as part of its $3.1 billion takeover of Carmot Therapeutics that was announced last year. A phase 1b trial ...

Roche and Zealand Pharma have entered into a partnership worth up to $5.3bn to advance Zealand’s mid-stage obesity candidate petrelintide.

Roche Holding agreed a collaboration and licensing deal with Zealand Pharma to co-develop a weight-loss treatment using its CT-388 medicine combined with Zealand Pharma’s petrelintide.